Are biosimilars for Nucala mandatory in the US?
Nucala is mepolizumab, a biologic. In the US, there is no general nationwide rule that forces patients to switch from an originator biologic (Nucala) to a specific biosimilar once one exists. Mandatory switching usually happens through insurance or formulary policies, not through a clinical law that applies to every patient.
When do insurers require switching to a biosimilar?
Health plans commonly require biosimilar use through:
- Step therapy (patients must try the biosimilar first)
- Formulary placement (biosimilars have preferred coverage)
- “Non-medical switching” rules (requiring a switch for cost reasons)
The exact trigger and how strictly it is enforced depends on the insurer, the plan contract, and any prior authorization requirements.
Can patients stay on Nucala instead of switching?
Often yes, but it depends on coverage rules. If a plan requires a switch, a prescriber typically can request an exception based on medical need (for example, stable control on Nucala, prior hypersensitivity, or other treatment-specific considerations). Approval is plan-specific.
Are there laws requiring biosimilar substitution at the pharmacy?
In some places, pharmacy-level substitution may be permitted or restricted by state rules. Whether pharmacists can substitute a biosimilar for an injected biologic without the prescriber’s permission varies by jurisdiction. This is one reason “mandatory” can feel different from one location to another.
What if a biosimilar becomes available for Nucala—does that automatically change eligibility?
Not automatically. Even after biosimilars are approved and available, coverage can lag or vary by plan. Some insurers update formularies quickly; others keep coverage for the originator with prior authorization.
What patients typically ask about during a required switch
People usually want to know:
- Whether the biosimilar works the same way for their condition
- Whether switching could affect symptom control
- Whether they will need new prior authorization
- Whether their dose and administration schedule will change
If you share your country and insurer, I can be more precise
Rules on “mandatory” biosimilars depend heavily on location and insurance policy. Tell me your country (and state/province if relevant) and whether you mean private insurance, Medicaid, Medicare, or a specific plan name.